SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-23-000491 to Scilex Holding Co (SCLX, SCLXW) (CIK 0001820190) (SCLX)

Scilex Holding Co (SCLX, SCLXW) (CIK 0001820190)
Date: Jan. 18, 2023 · CIK: 0001820190 · Accession: 0000000000-23-000491

AI Filing Summary & Sentiment

File numbers found in text: 333-269205

Date
January 18, 2023
Author
Not clearly detected
Form
UPLOAD
Company
Scilex Holding Co (SCLX, SCLXW) (CIK 0001820190)

Letter

United States securities and exchange commission logo January 18, 2023 Jaisim Shah Chief Executive Officer Scilex Holding Co 960 San Antonio Road Palo Alto, CA 94303 Re:Scilex Holding Co Registration Statement on Form S-1 Filed January 12, 2023 File No. 333-269205 Dear Jaisim Shah: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Elizabeth Razzano

Show Raw Text
United States securities and exchange commission logo
January 18, 2023
Jaisim Shah
Chief Executive Officer
Scilex Holding Co
960 San Antonio Road
Palo Alto, CA 94303
Re:Scilex Holding Co
Registration Statement on Form S-1
Filed January 12, 2023
File No. 333-269205
Dear Jaisim Shah:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Elizabeth Razzano